Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7075768 | 0.80 | ALDH1A1 (0.41) | KMT2ALMNAALDH1A1L3MBTL1SMN1; SMN2 | |
| SCHEMBL7076865 | 0.79 | LMNA (0.43) | KMT2ALMNAALDH1A1L3MBTL1SMN1; SMN2 | |
| SCHEMBL7082715 | 0.78 | PKM (0.48) | KMT2ALMNAALDH1A1L3MBTL1SMN1; SMN2 | |
| SCHEMBL7111882 | 0.78 | KMT2A (0.54) | KMT2ALMNAALDH1A1L3MBTL1SMN1; SMN2 | |
| SCHEMBL7076543 | 0.78 | KMT2A (0.52) | KMT2ALMNANAMPTSMN1; SMN2HTT | |
| SCHEMBL7075332 | 0.77 | MAPT (0.41) | KMT2ALMNAALDH1A1L3MBTL1SMN1; SMN2 | |
| SCHEMBL7075335 | 0.77 | ALDH1A1 (0.58) | KMT2ALMNAALDH1A1L3MBTL1SMN1; SMN2 | |
| SCHEMBL7080644 | 0.76 | LMNA (0.49) | KMT2ALMNAALDH1A1L3MBTL1SMN1; SMN2 | |
| SCHEMBL7076851 | 0.74 | KMT2A (0.45) | KMT2ALMNAALDH1A1L3MBTL1SMN1; SMN2 | |
| SCHEMBL8881389 | 0.73 | HTT (0.62) | KMT2AALDH1A1L3MBTL1SMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030158186-A1 | Compositions and methods for treating heart failure | CYTOKINETICS, INCORPORATED | 2003-08-21 | — | — | US | disclosed |
| WO-2003059265-A2 | COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE | CYTOKINETICS, INC. (US) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158186-A1 | Compositions and methods for treating heart failure | MYH2, TNNI3, MYLK2 | KMT2A 2747/4885LMNA 228/4885ALDH1A1 3435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.